Interventional Oncology Tumor Analysis and Therapy Solution Unveiled

A new interventional oncology solution for minimally invasive liver cancer treatment has been unveiled by a large medical imaging equipment manufacturer.

This is the first solution that is optimized for use with radiopaque beads that minimize damage to healthy tissue, and organs, during tumor treatment.


Royal Philips (Amsterdam, the Netherlands) introduced the OncoSuite solution that provides complete coverage of the liver enabling clinicians to visualize peripheral hepatic tumors, and provide analysis, and minimally invasive, targeted tumor lesion treatment. The solution gives clinicians an improved view of treatment targets during a procedure.

The Philips OncoSuite enhances tumor embolization and ablation procedures, and works together with Philips interventional X-Ray systems. The OncoSuite enables targeted treatment of an entire tumor, and feeder vessels, while minimizing damage to surrounding organs, and healthy tissues.

Minimally invasive, image-guided interventional oncology procedures provide an alternative for patients who cannot be treated using conventional surgery, chemotherapy or radiation therapy.

Dr. Jeff Geschwind, chairman and chief of the Department of Radiology and Biomedical Imaging, Yale School of Medicine, said, “While OncoSuite can be used for a number of different cancers including bone, kidney and lung, the solution and its specific tools have been optimized for the treatment of patients with liver cancer. Given the steady increase in the prevalence of non-alcoholic fatty liver disease and liver cancer, the development and availability of new technology is much needed to provide interventional oncologists with a breakthrough that allows best possible treatment for these patients.”

Related Links:
Royal Philips